New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Allogene Therapeutics, Inc. (ALLO) vs Clinuvel Pharmaceuticals Ltd. - Sponsored ADR (CUVL)

Allogene Therapeutics, Inc. and Clinuvel Pharmaceuticals Ltd. - Sponsored ADR are both Biotechnology companies. Allogene Therapeutics, Inc. and Clinuvel Pharmaceuticals Ltd. - Sponsored ADR are of similar size ($237.8M and $231.1M). Across the 1 metrics below, Allogene Therapeutics, Inc. leads on 1 and Clinuvel Pharmaceuticals Ltd. - Sponsored ADR on 0.

Valuation

Metric ALLO CUVL Biotechnology median
P/E n/m — 8.49
P/S 45.61 — 8.56
P/B 0.55 — 2.04
Price to free cash flow n/m — 23.84
EV/EBITDA 0.43 — 0.69
EV/Sales (16.66) — 8.00
Earnings yield (101.61%) — (35.81%)
Free cash flow yield (50.71%) — (25.41%)

Profitability

Metric ALLO CUVL Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (342,700.00%) — 0.00%
Net margin (335,973.56%) — 0.00%
Free cash flow margin (261,473.56%) — 0.00%
Return on equity (49.29%) — (51.58%)
Return on assets (36.69%) — (45.91%)
Return on invested capital (119.37%) — 0.00%

Growth

Metric ALLO CUVL Biotechnology median
Revenue growth (TTM) (30.40%) — 7.20%
EPS growth (last fiscal year) 34.09% (2.13%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ALLO CUVL Biotechnology median
Debt to equity 0.00 — 0.00
Current ratio 7.79 — 4.79
Net debt to EBITDA 1.24 — 1.01

Dividend

Metric ALLO CUVL Biotechnology median
Dividend yield — 0.62% 0.41%
Payout ratio — — —

Size

Metric ALLO CUVL Biotechnology median
Market cap 231.06m 237.81m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack